Corbus Pharmaceuticals Holdings, Inc.
corporate_fare Company Profile
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for CRBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CRBP spans 8-K, 424B5, 10-Q.
Recent high-impact activity:
- Corbus Details Full CANYON-1 Data: 5% Weight Loss at 60 mg, Clean Psychiatric Safety
- Corbus Posts $37.8M Q3 Loss; $115.3M Cash Funds Operations Into 2028
- Corbus Doses First Patient in Registrational TEMPO-1 Trial for CRB-701
- Corbus CRB-913 Hits 5% Weight Loss in Phase 1b Obesity Trial With Clean Safety
- Corbus' CRB-913 Obesity Drug Hits 5% Weight Loss in Phase 1b, Beats Safety Bar
Financial Snapshot
Short Interest & Short Volume
3.48 days to coverFINRA reported short interest of 3,244,229 shares in CRBP as of the October 30, 2026 settlement, a 19.5% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 49.5% of CRBP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CRBP, detected from its recent SEC filings · based on capital-structure filings through 2026-08-07.
$127.5M ATM Program Activated · Potential 70% Share Count Increase
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →